Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Orkla India Shares Debut Subdued on Stock Exchanges, Falling Below Expectations

Consumer Products

|

Updated on 06 Nov 2025, 05:43 am

Whalesbook Logo

Reviewed By

Simar Singh | Whalesbook News Team

Short Description:

Orkla India, owner of food brands MTR Foods, Eastern Condiments, and Rasoi Magic, made a muted debut on Indian stock exchanges (BSE and NSE) on Thursday. While listing slightly above its IPO price, the stock quickly saw a decline, trading below its issue price and the grey market premium expectations. The IPO was fully an Offer for Sale, indicating existing shareholders divested their stakes.
Orkla India Shares Debut Subdued on Stock Exchanges, Falling Below Expectations

▶

Detailed Coverage:

Orkla India's shares commenced trading on the BSE at ₹751.5, a marginal gain of 2.94% over its Initial Public Offering (IPO) price of ₹730. On the National Stock Exchange (NSE), the listing was at ₹750.10, a premium of 2.75%. However, post-listing, the stock experienced volatility, reaching a high of ₹755 and a low of ₹715 on the BSE. At the time of reporting, it was trading at ₹719, down 1.5% from its IPO price. The company's market capitalization stood at ₹9,849.53 crore.

The subdued listing was below market expectations and the grey market premium (GMP), which had previously indicated a listing closer to ₹796 per share. An analyst from Mehta Equities had predicted a listing gain of around 10–12%, which was not met. The IPO was entirely an Offer for Sale (OFS), meaning no new capital was raised by the company; only existing shareholders sold their stakes. Despite this, the issue saw strong subscription rates, with an overall subscription of 48.74 times, including robust interest from Qualified Institutional Buyers (QIBs) and High Net-worth Individuals (NIIs).

Impact: This subdued listing could affect investor sentiment towards upcoming food sector IPOs and the perception of Orkla India's valuation. It highlights the challenges companies face in achieving desired listing gains even with strong IPO subscriptions, especially in a flat market environment. Impact Rating: 5/10

**Definitions:**

* **Bourses**: Stock exchanges where securities like shares are bought and sold. * **Street expectations**: The general predictions and outlook of financial analysts and market participants regarding a company's performance or stock price. * **IPO (Initial Public Offering)**: The process where a private company first sells its shares to the public, becoming a publicly traded company. * **Grey market premium (GMP)**: An unofficial indicator where IPO shares trade at a premium or discount in the unlisted market before their official stock exchange listing. A positive GMP suggests high demand. * **Offer for Sale (OFS)**: A type of share sale where existing shareholders sell their stake to new investors. The company itself does not issue new shares or receive funds from this sale. * **Subscription**: The process of investors applying for shares during an IPO. An oversubscribed IPO means more shares were requested than available. * **QIB (Qualified Institutional Buyers)**: Large financial institutions like mutual funds, insurance companies, and foreign institutional investors that are eligible to invest in IPOs. * **NII (High Net-worth Individuals)**: Wealthy individuals who meet certain criteria and invest substantial amounts in financial markets.


Research Reports Sector

Goldman Sachs Upgrades India Equities to Overweight, Sets Nifty Target at 29,000 by 2026

Goldman Sachs Upgrades India Equities to Overweight, Sets Nifty Target at 29,000 by 2026

Goldman Sachs Upgrades India Equities to Overweight, Sets Nifty Target at 29,000 by 2026

Goldman Sachs Upgrades India Equities to Overweight, Sets Nifty Target at 29,000 by 2026


Healthcare/Biotech Sector

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns